Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
InfluentialNonalcoholic steatohepatitis: An expanded clinical entity
Bacon, B. R., Farahvash, M. J., Janney, C. G., & Neuschwander-Tetri, B. A. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90235-6 · Cited by 1,144 · cited 1×
“However, it has recently become clear that fatty liver is a precursor of the more advanced liver disease nonalcoholic steatohepatitis, a condition that may progress to cirrhosis in up to 25% of patients (3, 4).”
BackgroundAGA technical review on nonalcoholic fatty liver disease
Sanyal, A. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36572 · Cited by 1,072
Nonalcoholic fatty liver disease
Clark, J. M., Brancati, F. L., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33573 · Cited by 901
Abdominal Fat: Standardized Technique for Measurement at CT
Yoshizumi, T., Nakamura, T., Yamane, M., Waliul Islam, A. H. M., Menju, M., Yamasaki, K., Arai, T., Kotani, K., Funahashi, T., Yamashita, S., et al. (1999) · Radiology · doi:10.1148/radiology.211.1.r99ap15283 · Cited by 829
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726 · cited 1×
“Indeed, NAFLD patients treated with insulin-sensitizing agents show marked improvement in their condition (28, 30, 31).”
BackgroundMetformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Nonalcoholic steatohepatitis: A study of 49 patients
Lee, R. G. (1989) · Human Pathology · doi:10.1016/0046-8177(89)90249-9 · Cited by 550
Schwarz, J.-M., Linfoot, P., Dare, D., & Aghajanian, K. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.43 · Cited by 496 · cited 3×
“The healthy subjects’ lipogenesis rates tripled when measured in the fasting state after 5 days of high-carbohydrate feeding, while no change was observed in the fasting lipogenic rate of insulin-resistant subjects consuming the same diet (32).”
BackgroundDiraison, F., Moulin, P., & Beylot, M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70061-7 · Cited by 435
Radioactive and Stable Isotope Tracers in Biomedicine
Bramlet, R. (1993) · Clinical Nuclear Medicine · doi:10.1097/00003072-199305000-00027 · Cited by 395
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394 · cited 1×
“Indeed, NAFLD patients treated with insulin-sensitizing agents show marked improvement in their condition (28, 30, 31).”
BackgroundParks, E. J., Krauss, R. M., Christiansen, M. P., Neese, R. A., & Hellerstein, M. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6572 · Cited by 349
Self-citationApolipoprotein synthesis in nonalcoholic steatohepatitis
Charlton, M., Sreekumar, R., Rasmussen, D., Lindor, K., & Nair, S. K. (2002) · Hepatology · doi:10.1053/jhep.2002.32527 · Cited by 333
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Non‐alcoholic steatohepatitis: another disease of affluence
James, *., & Day, C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00163-4 · Cited by 271
Kinetics of triglyceride turnover of very low density lipoproteins of human plasma
Reaven, G. M., Hill, D. B., Gross, R. C., & Farquhar, J. W. (1965) · Journal of Clinical Investigation · doi:10.1172/jci105290 · Cited by 221
Hudgins, L. C., Hellerstein, M. K., Seidman, C. E., Neese, R. A., Tremaroli, J. D., & Hirsch, J. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32407-x · Cited by 216
Persistent hyperaminotransferasemia resolving after weight reduction in obese children
Vajro, P., Fontanella, A., Perna, C., Orso, G., Tedesco, M., & De Vincenzo, A. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70202-0 · Cited by 197
Farquhar, J. W., Gross, R. C., Wagner, R. M., & Reaven, G. M. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39649-8 · Cited by 189
CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & REAVEN, G. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-17 · Cited by 177
Temporal pattern of de novo lipogenesis in the postprandial state in healthy men1–3
Timlin, M. T., & Parks, E. J. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.35 · Cited by 172
Self-citationAbdominal fat assessed by computed tomography: Sex difference in distribution
Dixon, A. K. (1983) · Clinical Radiology · doi:10.1016/s0009-9260(83)80303-1 · Cited by 121 · cited 5×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
BackgroundInfluentialSystemic and Forearm Triglyceride Metabolism
Miles, J. M., Park, Y. S., Walewicz, D., Russell-Lopez, C., Windsor, S., Isley, W. L., Coppack, S. W., & Harris, W. S. (2004) · Diabetes · doi:10.2337/diabetes.53.3.521 · Cited by 114
Investigation of in vivo fatty acid metabolism in AFABP/aP2−/−mice
Baar, R. A., Dingfelder, C. S., Smith, L. A., Bernlohr, D. A., Wu, C., Lange, A. J., & Parks, E. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00256.2004 · Cited by 98 · cited 1×
“Data from mice in our lab confirm that this is the case in animals (19, 38).”
BackgroundSelf-citationInsulin resistance, adipose tissue and coronary heart disease
Frayn, K. N., & Coppack, S. W. (1992) · Clinical Science · doi:10.1042/cs0820001 · Cited by 97
Parks, E. J. (2002) · British Journal of Nutrition · doi:10.1079/bjn/2002544 · Cited by 82 · cited 3×
“The 24% DNL observed here is twice the 10% reported previously in obese, hyperinsulinemic subjects (32) and is 4–5 times the less than 5% observed in healthy populations (33, 34).”
BackgroundResultSelf-citationDonnelly, K. L., Margosian, M. R., Parks, E. J., Sheth, S. S., & Lusis, A. J. (2004) · Journal of Nutrition · doi:10.1093/jn/134.6.1475 · Cited by 64
Self-citationKooner, J. S., Baliga, R. R., Wilding, J., Crook, D., Packard, C. J., Banks, L. M., Peart, S., Aitman, T. J., & Scott, J. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.7.1021 · Cited by 61
Use of stable isotopically labeled tracers for studies of metabolic kinetics: An overview
Patterson, B. W. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90260-2 · Cited by 61
Hepatic Catabolism of Remnant Lipoproteins: Where the Action Is
Havel, R. J., & Hamilton, R. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000115382.53810.24 · Cited by 58
Hellerstein, M. K., Neese, R. A., & Schwarz, J. M. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.265.5.e814 · Cited by 56 · cited 4×
“Nonstandard abbreviations used: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DNL, de novo lipogenesis; GC/MS, gas chromatography/mass spectrometry; GCRC, General Clinical Research Center; HOMAIR, homeostasis model assessment of insulin resistance; MIDA, mass isotopomer distribution analysis; NAFLD,…”
MethodInfluentialBoberg, J., Carlson, L. A., & Freyschuss, U. (1972) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1972.tb00580.x · Cited by 52 · cited 2×
“Nonetheless, the estimate of hepatic TAG turnover time (5 × t1/2) ranged from 20 to 60 days, which was surprisingly long, given estimates of 1–2 days for liver TAG turnover in healthy subjects (16, 39, 41, 42).”
BackgroundResultMethods for measurement of fatty acid and cholesterol metabolism
Hellerstein, M. K. (1995) · Current Opinion in Lipidology · doi:10.1097/00041433-199506000-00010 · Cited by 35 · cited 4×
“Nonstandard abbreviations used: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DNL, de novo lipogenesis; GC/MS, gas chromatography/mass spectrometry; GCRC, General Clinical Research Center; HOMAIR, homeostasis model assessment of insulin resistance; MIDA, mass isotopomer distribution analysis; NAFLD,…”
MethodInfluentialNilsson, S., & Scherstén, T. (1969) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365516909080159 · Cited by 33
The use of computers to study rates of lipid metabolism
Baker, N. (1969) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42644-6 · Cited by 33
Marzetta, C. A., Foster, D., & Brunzell, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42737-3 · Cited by 29
LIPID COMPOSITION OF HUMAN LIVER BIOPSY SPECIMENS
LAURELL, S., & Lundquist, A. (1971) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1971.tb04339.x · Cited by 28 · cited 1×
“01 g per gram of tissue typically observed in healthy populations (25, 26).”
BackgroundNitrogen, Lipid, Glycogen and Deoxyribonucleic Acid Content of Human Liver
Martinsson, A., Sunzel, H., & HOOD, B. (1963) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1963.tb17461.x · Cited by 16
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
“The accumulation of triglycerides in the liver of obese humans is associated with the promotion of lipogenesis in hepatocytes (Donnelly et al., 2005).”
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781
“60% of fatty acids to newly synthesized triglyceride in the liver while DNL contributes 26%.(64) Rectal infusion of acetate and propionate has demonstrated a 40% reduction in serum FFA.”
BackgroundMechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.